

Molecular biology of bladder cancer: new insights into p

Nature Reviews Cancer

15, 25-41

DOI: [10.1038/nrc3817](https://doi.org/10.1038/nrc3817)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent Mechanisms. <i>Translational Oncology</i> , 2015, 8, 387-399.	1.7	6
2	Complexity of FGFR signalling in metastatic urothelial cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 119.	6.9	28
3	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	0.9	17
4	Sox4 Expression Confers Bladder Cancer Stem Cell Properties and Predicts for Poor Patient Outcome. <i>International Journal of Biological Sciences</i> , 2015, 11, 1363-1375.	2.6	27
5	Comparative Aspects of BRAF Mutations in Canine Cancers. <i>Veterinary Sciences</i> , 2015, 2, 231-245.	0.6	25
6	Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. <i>Proteomes</i> , 2015, 3, 266-282.	1.7	5
7	EZH2 in Bladder Cancer, a Promising Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27107-27132.	1.8	57
8	Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer. <i>PLoS Genetics</i> , 2015, 11, e1005689.	1.5	68
9	Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets. <i>Current Genomics</i> , 2015, 17, 33-61.	0.7	3
10	Integrative Analysis with Monte Carlo Cross-Validation Reveals miRNAs Regulating Pathways Cross-Talk in Aggressive Breast Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-17.	0.9	30
12	Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. <i>Eur Urol</i> 2014;66:609-10. <i>European Urology</i> , 2015, 67, e73-e75.	0.9	4
13	Effect of pathogenic bacteria on reliability of CK-19, CK-20 and UPII as bladder cancer genetic markers: A molecular biology study. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2015, 2, 176-182.	0.2	4
14	On Molecular Classification of Bladder Cancer: Out of One, Many. <i>European Urology</i> , 2015, 68, 921-923.	0.9	47
15	Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studies. <i>BBA Clinical</i> , 2015, 4, 27-34.	4.1	39
18	Waterworks. <i>Acta Physiologica</i> , 2015, 214, 147-148.	1.8	0
19	Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. <i>Clinical Cancer Research</i> , 2015, 21, 4514-4524.	3.2	110
20	Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. <i>Clinical Epigenetics</i> , 2015, 7, 109.	1.8	60
21	The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. <i>Seminars in Cancer Biology</i> , 2015, 35, 125-132.	4.3	20

#	ARTICLE	IF	CITATIONS
22	The emerging role of the androgen receptor in bladder cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R265-R277.	1.6	55
23	Homozygous losses detected by array comparative genomic hybridization in multiplex urothelial carcinomas of the bladder. <i>Cancer Genetics</i> , 2015, 208, 434-440.	0.2	10
24	Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters. <i>Neoplasia</i> , 2015, 17, 574-585.	2.3	10
25	Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. <i>Nature</i> , 2015, 517, 209-213.	13.7	500
26	Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis. <i>Neoplasia</i> , 2016, 63, 952-960.	0.7	8
27	Novel non invasive diagnostic strategies in bladder cancer. <i>Medicine and Pharmacy Reports</i> , 2016, 89, 187-192.	0.2	11
28	Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. <i>Oncotarget</i> , 2016, 7, 14153-14160.	0.8	43
29	High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. <i>Oncotarget</i> , 2016, 7, 9102-9117.	0.8	24
30	Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4535-4544.	3.3	25
31	An Efficient Light-Inducible P53 Expression System for Inhibiting Proliferation of Bladder Cancer Cell. <i>International Journal of Biological Sciences</i> , 2016, 12, 1273-1278.	2.6	26
32	Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2016, 17, 43.	1.8	42
33	Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 271.	1.8	9
34	Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes. <i>Disease Markers</i> , 2016, 2016, 1-5.	0.6	60
35	Spectrum of genomic alterations in <i>FGFR3</i> : current appraisal of the potential role of <i>FGFR3</i> in advanced urothelial carcinoma. <i>BJU International</i> , 2016, 118, 681-691.	1.3	15
36	<i>KLF5</i> promotes cell migration by up-regulating <i>FYN</i> in bladder cancer cells. <i>FEBS Letters</i> , 2016, 590, 408-418.	1.3	32
37	MicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids. <i>International Journal of Cancer</i> , 2016, 138, 2334-2345.	2.3	55
38	Biomarkers in bladder cancer: A metabolomic approach using <i>in vitro</i> and <i>ex vivo</i> model systems. <i>International Journal of Cancer</i> , 2016, 139, 256-268.	2.3	62
39	Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. <i>International Journal of Cancer</i> , 2016, 138, 2562-2569.	2.3	34

#	ARTICLE	IF	CITATIONS
40	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016, 122, 702-711.	2.0	81
41	Detecting coordinated regulations of pathways by higher logic analysis. , 2016, , .		0
42	PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. <i>BMC Cancer</i> , 2016, 16, 553.	1.1	25
43	A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 301-317.	0.2	79
45	Urothelial carcinoma management in elderly or unfit patients. <i>European Journal of Cancer</i> , Supplement, 2016, 14, 1-20.	2.2	45
46	Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness. <i>Cell Cycle</i> , 2016, 15, 368-380.	1.3	30
47	Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. <i>Epigenetics</i> , 2016, 11, 237-246.	1.3	36
48	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016, 70, 611-620.	0.9	120
49	Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. <i>International Journal of Epidemiology</i> , 2016, 45, 857-870.	0.9	148
50	Intrinsic subtypes and bladder cancer metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 260-267.	0.5	31
51	Immunomodulatory proteins FIP-gts and chloroquine induce caspase-independent cell death via autophagy for resensitizing cisplatin-resistant urothelial cancer cells. <i>Phytomedicine</i> , 2016, 23, 1566-1573.	2.3	26
52	DNA methylation in urothelial carcinoma. <i>Epigenomics</i> , 2016, 8, 1415-1428.	1.0	21
53	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. <i>Cancer Research</i> , 2016, 76, 5894-5906.	0.4	87
54	Magnetic nanowires for rapid and ultrasensitive isolation of DNA from cervical specimens for the detection of multiple human papillomaviruses genotypes. <i>Biosensors and Bioelectronics</i> , 2016, 86, 864-870.	5.3	15
55	An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. <i>Cancer Cell</i> , 2016, 30, 432-443.	7.7	58
56	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. <i>Molecular Oncology</i> , 2016, 10, 1450-1460.	2.1	44
57	The Emerging Molecular Landscape of Urothelial Carcinoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 391-404.	0.7	30
58	Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. <i>BMC Cancer</i> , 2016, 16, 653.	1.1	36

#	ARTICLE	IF	CITATIONS
59	Meta-analysis of microRNAs as biomarkers for muscle-invasive bladder cancer. <i>Biomedical Reports</i> , 2016, 5, 159-164.	0.9	4
60	Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. <i>Targeted Oncology</i> , 2016, 11, 783-798.	1.7	52
61	A place for precision medicine in bladder cancer: targeting the FGFRs. <i>Future Oncology</i> , 2016, 12, 2243-2263.	1.1	39
62	Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. <i>Histopathology</i> , 2016, 69, 717-726.	1.6	14
63	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016, 48, 1490-1499.	9.4	250
64	Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. <i>BMC Medicine</i> , 2016, 14, 163.	2.3	43
65	Conditional ablation of TGF- β 2 signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model. <i>Scientific Reports</i> , 2016, 6, 29479.	1.6	40
66	FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 25596.	1.6	8
67	Aldo-keto reductase 1C1 induced by interleukin-1 β 2 mediates the invasive potential and drug resistance of metastatic bladder cancer cells. <i>Scientific Reports</i> , 2016, 6, 34625.	1.6	58
68	The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. <i>Scientific Reports</i> , 2016, 6, 20574.	1.6	102
69	Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project. <i>Cancer Causes and Control</i> , 2016, 27, 1429-1435.	0.8	18
70	The translational potential of microRNAs as biofluid markers of urological tumours. <i>Nature Reviews Urology</i> , 2016, 13, 734-752.	1.9	104
71	BcCluster: A Bladder Cancer Database at the Molecular Level. <i>Bladder Cancer</i> , 2016, 2, 65-76.	0.2	4
72	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.2	30
73	ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPES. , 2016, , .		36
74	C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation. <i>Journal of Translational Medicine</i> , 2016, 14, 55.	1.8	9
75	Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1726-1739.	1.9	10
76	Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer. <i>Gene</i> , 2016, 591, 320-326.	1.0	9

#	ARTICLE	IF	CITATIONS
77	Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2016, 2, 445-452.	1.6	63
78	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. <i>European Urology</i> , 2016, 70, 75-82.	0.9	174
79	Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 2981-2992.	3.2	78
80	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016, 24, 1167-1174.	1.4	115
81	Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 299-312.	1.9	48
82	The Paris System for Reporting Urinary Cytology. , 2016, , .		127
83	Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 347-359.	1.9	30
84	Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway. <i>Journal of Proteome Research</i> , 2016, 15, 1333-1341.	1.8	23
85	The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 4.e1-4.e9.	0.8	19
86	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.2	36
88	Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 122-129.	0.9	14
89	Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway. <i>British Journal of Cancer</i> , 2016, 114, 305-313.	2.9	11
90	Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. <i>Journal of Urology</i> , 2016, 195, 872-879.	0.2	42
91	H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. <i>Tumor Biology</i> , 2016, 37, 263-270.	0.8	92
92	Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 196-202.	0.6	34
93	Urinary biomarkers for the diagnosis of urothelial bladder cancer. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 221.	0.5	1
94	FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression. <i>Human Pathology</i> , 2017, 62, 222-231.	1.1	16
95	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2017, 77, 1035-1046.	0.4	15

#	ARTICLE	IF	CITATIONS
96	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 401-414.	1.5	28
97	Role of Imaging in the Local Staging of Urothelial Carcinoma of the Bladder. <i>American Journal of Roentgenology</i> , 2017, 208, 1193-1205.	1.0	59
98	PlcKIng on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets. <i>European Urology</i> , 2017, 71, 863-865.	0.9	1
99	Non-muscle-invasive bladder cancer: a vision for the future. <i>Scandinavian Journal of Urology</i> , 2017, 51, 87-94.	0.6	33
100	Epithelialâ€mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. <i>Laboratory Investigation</i> , 2017, 97, 567-576.	1.7	40
101	Exploration of bladder cancer molecular mechanisms based on miRNA-mRNA regulatory network. <i>Oncology Reports</i> , 2017, 37, 1461-1468.	1.2	10
102	Bladder cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17022.	18.1	590
103	Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status. <i>Journal of Biosciences</i> , 2017, 42, 91-101.	0.5	22
104	Biomarkers for precision medicine in bladder cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 207-213.	1.0	30
106	Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells. <i>Investigational New Drugs</i> , 2017, 35, 671-681.	1.2	31
107	Combining Protein and miRNA Quantification for Bladder Cancer Analysis. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 23420-23427.	4.0	39
108	Adequacy of voided urine specimens prepared by ThinPrep and evaluated using The Paris System for Reporting Urinary Cytology. <i>Journal of the American Society of Cytopathology</i> , 2017, 6, 155-161.	0.2	13
109	The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1971-1976.	1.2	41
110	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	0.9	195
111	p53 immunohistochemistry in highâ€grade urothelial carcinoma of the bladder is prognostically significant. <i>Histopathology</i> , 2017, 71, 296-304.	1.6	37
112	Carbonic anhydrase 2 is a novel invasionâ€associated factor in urinary bladder cancers. <i>Cancer Science</i> , 2017, 108, 331-337.	1.7	12
113	Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. <i>Scientific Reports</i> , 2017, 7, 45983.	1.6	69
114	Identification of novel potential genetic predictors of urothelial bladder carcinoma susceptibility in Pakistani population. <i>Familial Cancer</i> , 2017, 16, 577-594.	0.9	9

#	ARTICLE	IF	CITATIONS
115	Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 395.	1.6	117
116	Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, .	7.1	35
117	Parasite Infection, Carcinogenesis and Human Malignancy. <i>EBioMedicine</i> , 2017, 15, 12-23.	2.7	108
118	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	13.5	1,742
119	Noninvasive detection of bladder cancer via expression-targeted gene delivery. <i>Journal of Gene Medicine</i> , 2017, 19, 366-375.	1.4	2
120	The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer. <i>Cytotherapy</i> , 2017, 19, 1233-1245.	0.3	5
121	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. <i>Annals of Oncology</i> , 2017, 28, 2458-2463.	0.6	68
122	BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7388-7399.	3.2	162
123	Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. <i>Oncology Letters</i> , 2017, 14, 3817-3824.	0.8	29
124	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 758-766.	1.5	21
125	Phthalazino[1,2- <i>b</i>]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6853-6866.	2.9	42
126	Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. <i>Pharmacogenomics</i> , 2017, 18, 1167-1178.	0.6	7
127	Evasion of immunosurveillance by genomic alterations of PPAR γ /RXR α in bladder cancer. <i>Nature Communications</i> , 2017, 8, 103.	5.8	107
129	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2017, 14, 2468-2474.	0.8	6
130	p63 protein up-regulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wasf3/Wave3/MMP9 signaling and bladder cancer invasion. <i>Journal of Biological Chemistry</i> , 2017, 292, 15952-15963.	1.6	23
131	Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6592-6601.	3.2	43
132	Precursor Lesions of Urologic Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1615-1632.	1.2	6
133	Colon cancer associated transcripts in human cancers. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 531-540.	2.5	32

#	ARTICLE	IF	CITATIONS
134	Nuclear features of infiltrating urothelial carcinoma are distinguished from low-grade noninvasive papillary urothelial carcinoma by image analysis. <i>Oncology Letters</i> , 2017, 14, 2715-2722.	0.8	5
135	Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. <i>Cancer Cell</i> , 2017, 32, 701-715.e7.	7.7	224
136	Lower tract neoplasm: Update of imaging evaluation. <i>European Journal of Radiology</i> , 2017, 97, 119-130.	1.2	10
137	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 272-294.	0.1	6
138	Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 347-353.	1.4	2
139	Data-driven prediction of adverse drug reactions induced by drug-drug interactions. <i>BMC Pharmacology & Toxicology</i> , 2017, 18, 44.	1.0	35
140	Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 1.	3.5	76
141	Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 67-73.	0.6	15
142	Reply from Authors re: Xue-Ru Wu. Attention to Detail by Single-cell sequencing. <i>Eur Urol</i> 2017;71:13â€“4. <i>European Urology</i> , 2017, 71, 15-16.	0.9	1
143	Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patientsâ€™ prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 521-532.	1.2	16
144	Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. <i>Urology</i> , 2017, 102, 7-16.	0.5	15
146	Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of <i>CDKN2A</i> deletions in the <i>FGFR3</i> pathway. <i>Histopathology</i> , 2017, 70, 281-289.	1.6	35
147	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2017, 24, 7-15.	0.5	12
149	Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1266-1279.	1.6	69
150	The role of immunohistochemical expression of OCT-4 and SOX2 as predictors of recurrence and progression in superficial urinary bladder carcinoma. <i>Egyptian Journal of Pathology</i> , 2017, 37, 17-27.	0.0	1
151	Expression of HER2 and topoisomerase II β in urinary bladder transitional and squamous cell carcinoma. <i>Egyptian Journal of Pathology</i> , 2017, 37, 145-153.	0.0	0
152	CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatment Strategy for Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 79-88.	0.2	21
153	Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. <i>Oncotarget</i> , 2017, 8, 70982-71001.	0.8	42

#	ARTICLE	IF	CITATIONS
154	Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application. <i>Theranostics</i> , 2017, 7, 3559-3572.	4.6	60
155	Long noncoding RNA ASAP1-IT1 promotes cancer stemness and predicts a poor prognosis in patients with bladder cancer. <i>Neoplasma</i> , 2017, 64, 847-855.	0.7	31
156	Androgen Receptor Signaling in Bladder Cancer. <i>Cancers</i> , 2017, 9, 20.	1.7	73
157	MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype. <i>Genes</i> , 2017, 8, 77.	1.0	19
158	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. <i>Frontiers in Medicine</i> , 2017, 4, 30.	1.2	13
159	The Diagnostic Value of Nuclear Matrix Proteins in Bladder Cancer in the Aspect of Environmental Risk from Carcinogens. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	8
160	Illumination of a Vision—How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2463.	1.8	2
161	Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1673-1686.	1.0	21
162	Helminth infection—induced malignancy. <i>PLoS Pathogens</i> , 2017, 13, e1006393.	2.1	47
163	Prognostic Impact of a 12-gene Progression Score in Non—muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. <i>European Urology</i> , 2017, 72, 461-469.	0.9	74
164	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959.	0.9	263
165	Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. <i>Oncotarget</i> , 2017, 8, 35412-35424.	0.8	53
166	Clinical and <i>in vitro</i> analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer. <i>International Journal of Biological Sciences</i> , 2017, 13, 1373-1386.	2.6	29
167	Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. <i>International Journal of Oncology</i> , 2017, 51, 579-586.	1.4	26
168	Identification of hub miRNA biomarkers for bladder cancer by weighted gene coexpression network analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5551-5559.	1.0	13
169	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. <i>Oncotarget</i> , 2017, 8, 69435-69455.	0.8	27
170	Liquid biopsies for bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 331-335.	0.6	33
171	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 423-431.	0.8	16

#	ARTICLE	IF	CITATIONS
172	Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 749-758.	1.4	43
173	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. <i>Cell</i> , 2018, 173, 515-528.e17.	13.5	540
175	A DDX31/Mutant p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2018, 78, 2233-2247.	0.4	30
176	Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. <i>Clinical Cancer Research</i> , 2018, 24, 1586-1593.	3.2	79
177	TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer. <i>Cell Death and Disease</i> , 2018, 9, 72.	2.7	20
178	A practical guide to bladder cancer pathology. <i>Nature Reviews Urology</i> , 2018, 15, 143-154.	1.9	36
179	Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 448-459.	3.0	112
180	Pathophysiology of Bladder Cancer. , 2018, , 33-41.		3
181	Modeling Bladder Cancer with Genetic Engineering: Fidelity of Human-to-Laboratory Models. <i>Molecular Pathology Library</i> , 2018, , 221-237.	0.1	0
182	Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from the Cancer Genome Atlas (TCGA) Project. <i>Molecular Pathology Library</i> , 2018, , 43-64.	0.1	0
183	The evolving genomic landscape in urothelial cancer. <i>Current Opinion in Oncology</i> , 2018, 30, 197-202.	1.1	7
184	Genome-Wide DNA Methylation in Prediagnostic Blood and Bladder Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 689-695.	1.1	11
185	RE: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1273-1274.	3.0	1
186	Role of the androgen receptor in urothelial cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 465, 73-81.	1.6	41
187	SATB1 and bladder cancer: Is there a functional link?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 93.e13-93.e21.	0.8	7
188	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700074.	0.8	21
190	Asthma status is associated with decreased risk of aggressive urothelial bladder cancer. <i>International Journal of Cancer</i> , 2018, 142, 470-476.	2.3	10
191	Natural Agents-Mediated Targeting of Histone Deacetylases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 31-44.	1.0	5

#	ARTICLE	IF	CITATIONS
192	Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 251-273.	0.4	6
193	Spheroid Cultures of Primary Urothelial Cancer Cells: Cancer Tissue-Originated Spheroid (CTOS) Method. <i>Methods in Molecular Biology</i> , 2018, 1655, 145-153.	0.4	18
194	Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. <i>Methods in Molecular Biology</i> , 2018, 1655, 335-350.	0.4	117
195	TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPAR β -SIRT1 feedback loop in human bladder cancer cells. <i>Cancer Letters</i> , 2018, 414, 278-293.	3.2	58
196	YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. <i>Cancer Research</i> , 2018, 78, 168-181.	0.4	77
197	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	3.2	85
198	<i>Ganoderma microsporum</i> immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4592-4606.	1.2	13
199	The Rho GTPase signalling pathway in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 83-91.	1.9	15
200	Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1176-1189.	3.2	43
202	Three-dimensional organoid culture reveals involvement of Wnt/ β -catenin pathway in proliferation of bladder cancer cells. <i>Oncotarget</i> , 2018, 9, 11060-11070.	0.8	46
203	Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018, 4, 472-480.	1.6	8
204	Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. <i>Oncotarget</i> , 2018, 9, 28514-28531.	0.8	8
205	Foreground Detection with Deeply Learned Multi-Scale Spatial-Temporal Features. <i>Sensors</i> , 2018, 18, 4269.	2.1	17
206	Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder (Review). <i>Molecular and Clinical Oncology</i> , 2019, 10, 205-213.	0.4	23
207	Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients. <i>Oncology Letters</i> , 2018, 17, 201-208.	0.8	6
209	PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. <i>International Journal of Biological Sciences</i> , 2018, 14, 1883-1891.	2.6	110
210	Novel protein signatures suggest progression to muscular invasiveness in bladder cancer. <i>PLoS ONE</i> , 2018, 13, e0206475.	1.1	4
211	Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. <i>BMC Cancer</i> , 2018, 18, 1239.	1.1	16

#	ARTICLE	IF	CITATIONS
212	Long noncoding RNA LINC01296 promotes cancer-cell proliferation and metastasis in urothelial carcinoma of the bladder. <i>OncoTargets and Therapy</i> , 2018, Volume 12, 75-85.	1.0	20
213	The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression. <i>Cancers</i> , 2018, 10, 484.	1.7	15
214	Inhibition of TPL2 by interferon- β suppresses bladder cancer through activation of PDE4D. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 288.	3.5	14
215	UCA1 overexpression is associated with less aggressive subtypes of bladder cancer. <i>Oncology Reports</i> , 2018, 40, 2497-2506.	1.2	10
216	Low molecular weight proteins and enzymes in the urine of patients with bladder cancer - a pilot study. <i>Central European Journal of Urology</i> , 2018, 71, 280-286.	0.2	3
217	CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. <i>British Journal of Cancer</i> , 2018, 119, 961-970.	2.9	27
218	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	1.8	17
219	Multiregion segmentation of bladder cancer structures in MRI with progressive dilated convolutional networks. <i>Medical Physics</i> , 2018, 45, 5482-5493.	1.6	60
220	The latest treatment options for bladder cancer. <i>British Medical Bulletin</i> , 2018, 128, 85-95.	2.7	33
221	Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1477-1486.	2.9	41
222	3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer. <i>Journal of Visualized Experiments</i> , 2018, . .	0.2	2
223	miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 239-252.	1.0	47
224	Upregulation of Long Noncoding RNA TUG1 Promotes Bladder Cancer Cell Proliferation, Migration, and Invasion by Inhibiting miR-29c. <i>Oncology Research</i> , 2018, 26, 1083-1091.	0.6	37
226	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 Δ C>A/T Mutation. <i>Bladder Cancer</i> , 2018, 4, 41-48.	0.2	40
227	Diagnostic and Prognostic Implications of FGFR3 ^{high} /Ki67 ^{high} Papillary Bladder Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2548.	1.8	14
228	Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2568.	1.8	15
229	Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 22-37.	0.7	17
230	Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2514.	1.8	68

#	ARTICLE	IF	CITATIONS
231	The Cancer Genome Atlas Project in Bladder Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 259-271.	0.2	16
232	<i>LINC00857</i> expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2018, 7, 3342-3350.	1.3	31
233	Molecularly-driven precision medicine for advanced bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1749-1757.	1.2	4
234	STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4145-4153.	3.2	23
235	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. <i>Oncogene</i> , 2018, 37, 5858-5872.	2.6	20
236	PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein. <i>Oncogene</i> , 2018, 37, 5735-5748.	2.6	27
237	Promoter methylation analysis of <i>CDH1</i> and <i>p14ARF</i> genes in patients with urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4189-4196.	1.0	5
238	Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis. <i>EBioMedicine</i> , 2018, 34, 94-107.	2.7	19
239	Bladder Cancer: New Insights into Its Molecular Pathology. <i>Cancers</i> , 2018, 10, 100.	1.7	77
240	Evaluation of a New Survivin ELISA and UBCA® Rapid for the Detection of Bladder Cancer in Urine. <i>International Journal of Molecular Sciences</i> , 2018, 19, 226.	1.8	23
241	Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1613.	1.8	7
242	Amyloid precursor protein is overexpressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors. <i>International Journal of Urology</i> , 2018, 25, 808-816.	0.5	7
243	Unmasking molecular profiles of bladder cancer. <i>Investigative and Clinical Urology</i> , 2018, 59, 72.	1.0	23
244	Notch Pathway: Bioinformatic Analysis of Related Transcription Factors within Bladder Cancer Types and Subtypes. <i>Irbm</i> , 2018, 39, 261-267.	3.7	0
245	Anti-EGFR Indocyanine Green-Mitomycin C-Loaded Perfluorocarbon Double Nanoemulsion: A Novel Nanostructure for Targeted Photochemotherapy of Bladder Cancer Cells. <i>Nanomaterials</i> , 2018, 8, 283.	1.9	17
246	Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis. <i>Biochemistry (Moscow)</i> , 2018, 83, 930-943.	0.7	4
247	ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?. <i>PLoS ONE</i> , 2018, 13, e0202965.	1.1	25
248	Decreased c-Myc mRNA Stability via the MicroRNA 141-3p/AUF1 Axis Is Crucial for p63 ^Δ Inhibition of Cyclin D1 Gene Transcription and Bladder Cancer Cell Tumorigenicity. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	16

#	ARTICLE	IF	CITATIONS
249	Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion. <i>Oncology Letters</i> , 2018, 15, 6770-6776.	0.8	6
250	Predicting pathway cross-talks in ankylosing spondylitis through investigating the interactions among pathways. <i>Brazilian Journal of Medical and Biological Research</i> , 2018, 51, e6698.	0.7	2
251	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. <i>Human Pathology</i> , 2018, 80, 55-64.	1.1	36
252	Bladder cancer recurrence surveillance by urine metabolomics analysis. <i>Scientific Reports</i> , 2018, 8, 9172.	1.6	54
253	Smoking intensity and bladder cancer aggressiveness at diagnosis. <i>PLoS ONE</i> , 2018, 13, e0194039.	1.1	29
254	Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 165-172.	1.2	7
255	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUDâ€“SIU joint consultation on bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 3-13.	1.2	42
256	Nimbolide Represses the Proliferation, Migration, and Invasion of Bladder Carcinoma Cells via Chk2-Mediated G2/M Phase Cell Cycle Arrest, Altered Signaling Pathways, and Reduced Transcription Factors-Associated MMP-9 Expression. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-12.	0.5	14
257	TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0220173.	1.1	6
258	Does it matter whether a T1 high-grade tumor is molecularly classified?. <i>European Urology Oncology</i> , 2019, 4, 837-842.	2.6	1
259	A review on the accuracy of bladder cancer detection methods. <i>Journal of Cancer</i> , 2019, 10, 4038-4044.	1.2	87
260	Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151397.	0.6	26
261	Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 292.	3.5	15
262	Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 436-442.	0.9	7
263	Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelialâ€“mesenchymal transition via Akt/ GSK 3 β signaling. <i>Cancer Science</i> , 2019, 110, 2822-2833.	1.7	17
264	Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 322.	3.5	23
265	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 338-348.	13.9	885
266	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. <i>Histopathology</i> , 2019, 75, 865-875.	1.6	35

#	ARTICLE	IF	CITATIONS
267	Prognostic Impact of Canonical TGF- β 2 Signaling in Urothelial Bladder Cancer. <i>Medicina (Lithuania)</i> , 2019, 55, 302.	0.8	16
268	Erdafitinib in Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 1593-1595.	13.9	4
269	Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 787-800.	2.3	71
270	β -Np63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3075-3087.	1.2	4
272	Education for Sustainable Development: Global Progress and China's Experience. <i>Chinese Journal of Urban and Environmental Studies</i> , 2019, 07, 1940001.	0.5	1
273	Microstructure-Based Modeling of Mechanical Properties and Deformation Behavior of DP600 Dual Phase Steel. <i>Steel Research International</i> , 2019, 90, 1900311.	1.0	6
274	The histone demethylase UTX/KDM6A in cancer: Progress and puzzles. <i>International Journal of Cancer</i> , 2019, 145, 614-620.	2.3	60
275	Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. <i>Scientific Reports</i> , 2019, 9, 14476.	1.6	8
276	Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. <i>Frontiers in Genetics</i> , 2019, 10, 1125.	1.1	28
277	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. <i>Cancer Epidemiology</i> , 2019, 62, 101584.	0.8	4
278	Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1030.	1.3	51
279	The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer. <i>BMC Cancer</i> , 2019, 19, 991.	1.1	12
280	Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. <i>Cancers</i> , 2019, 11, 1219.	1.7	32
281	Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12818.	1.3	46
282	Exploration of bladder cancer-associated methylated miRNAs by methylated DNA immunoprecipitation sequencing. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6165-6174.	1.0	5
283	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2019, 120, 132-139.	1.3	24
284	MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2725-2736.	1.2	30
285	c-Met activation leads to the establishment of a TGF- β 2-receptor regulatory network in bladder cancer progression. <i>Nature Communications</i> , 2019, 10, 4349.	5.8	44

#	ARTICLE	IF	CITATIONS
286	The association between matrix metalloproteinase-7 genetic variant and bladder cancer risk in a Chinese Han population. <i>Clinical and Experimental Medicine</i> , 2019, 19, 565-570.	1.9	9
287	Identification and validation of an individualized autophagy-clinical prognostic index in bladder cancer patients. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3695-3712.	1.0	37
288	MicroRNA-143/Musashi2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer. <i>Cancer Science</i> , 2019, 110, 2189-2199.	1.7	27
289	MOGSA: Integrative Single Sample Gene-set Analysis of Multiple Omics Data. <i>Molecular and Cellular Proteomics</i> , 2019, 18, S153-S168.	2.5	59
290	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3K γ Inhibitor TAK-117 in Preclinical Bladder Cancer Models. <i>Molecular Cancer Research</i> , 2019, 17, 1931-1944.	1.5	23
291	Upregulation of NPL4 promotes bladder cancer cell proliferation by inhibiting DXO destabilization of cyclin D1 mRNA. <i>Cancer Cell International</i> , 2019, 19, 149.	1.8	8
292	Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2599.	1.8	18
293	Transcriptionally elevation of miR-494 by new ChIA-F compound via a HuR/JunB axis inhibits human bladder cancer cell invasion. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 822-833.	0.9	4
294	Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 645-653.	1.1	3
295	OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 466.	1.3	55
296	Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. <i>Oncolmmunology</i> , 2019, 8, e1577125.	2.1	10
297	Distinct mutational landscape of inverted urothelial papilloma. <i>Journal of Pathology</i> , 2019, 249, 3-5.	2.1	14
298	Urinary peptide panel for prognostic assessment of bladder cancer relapse. <i>Scientific Reports</i> , 2019, 9, 7635.	1.6	12
299	Long non-coding RNAs in genitourinary malignancies: a whole new world. <i>Nature Reviews Urology</i> , 2019, 16, 484-504.	1.9	80
300	E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma. <i>Cancer Biomarkers</i> , 2019, 25, 223-232.	0.8	19
301	Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. <i>Nature Communications</i> , 2019, 10, 2131.	5.8	27
302	Flaccidoxide-13-Acetate-Induced Apoptosis in Human Bladder Cancer Cells is through Activation of p38/JNK, Mitochondrial Dysfunction, and Endoplasmic Reticulum Stress Regulated Pathway. <i>Marine Drugs</i> , 2019, 17, 287.	2.2	21
303	KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108924.	2.5	24

#	ARTICLE	IF	CITATIONS
304	Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell. <i>Frontiers in Oncology</i> , 2019, 9, 203.	1.3	11
305	Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. <i>Molecular Pharmacology</i> , 2019, 96, 36-46.	1.0	22
306	Review on gender differences in non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 12-20.	0.6	15
307	The encouraging role of long noncoding RNA small nuclear RNA host gene 16 in epithelial-mesenchymal transition of bladder cancer via directly acting on miR-17-5p/metalloproteinases 3 axis. <i>Molecular Carcinogenesis</i> , 2019, 58, 1465-1480.	1.3	27
308	Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1625-1633.	1.2	9
309	Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1285.	1.8	16
310	Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. <i>Carcinogenesis</i> , 2019, 40, 965-974.	1.3	14
312	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	1.8	47
313	Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis. <i>Scientific Reports</i> , 2019, 9, 5174.	1.6	33
314	BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle-invasive bladder cancers: A microarray pathway analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3905-3915.	1.6	18
315	Prognostic value of differentially methylated gene profiles in bladder cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 18763-18772.	2.0	11
316	Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. <i>Journal of Pathology</i> , 2019, 248, 230-242.	2.1	32
317	Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1076-1084.	2.8	43
318	Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer. <i>American Journal of Pathology</i> , 2019, 189, 619-631.	1.9	39
319	Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer. <i>Nature Communications</i> , 2019, 10, 720.	5.8	57
320	Mathematical modeling of the dynamics of the bladder cancer and the immune response applied to a patient: Evolution and short-term prediction. <i>Mathematical Methods in the Applied Sciences</i> , 2019, 42, 5746-5757.	1.2	2
321	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 24.	1.8	16
322	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34

#	ARTICLE	IF	CITATIONS
323	Advancements in the clinical management of upper tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 1051-1060.	1.1	6
324	Identification of an immunotherapy-responsive molecular subtype of bladder cancer. EBioMedicine, 2019, 50, 238-245.	2.7	88
325	Upregulation of FGFR3 and HIF-1 α expression in muscle invasive bladder cancer. Medical Journal of Indonesia, 2019, 28, 3-7.	0.2	0
326	Molecular subtyping of bladder cancer. Current Opinion in Urology, 2019, 29, 198-202.	0.9	4
327	Urothelial Carcinoma In Situ (CIS): New Insights. Advances in Anatomic Pathology, 2019, 26, 313-319.	2.4	9
328	Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?. Advances in Anatomic Pathology, 2019, 26, 251-256.	2.4	9
329	The long noncoding RNA HIF1A α -AS2 facilitates cisplatin resistance in bladder cancer. Journal of Cellular Biochemistry, 2019, 120, 243-252.	1.2	47
330	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. European Urology, 2019, 75, 423-432.	0.9	205
331	SIU α -ICUD consultation on bladder cancer: basic science. World Journal of Urology, 2019, 37, 15-29.	1.2	3
332	Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. European Urology, 2019, 75, 853-860.	0.9	68
333	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research, 2019, 25, 2458-2470.	3.2	102
334	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discovery, 2019, 9, 500-509.	7.7	143
335	Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer. Clinical Cancer Research, 2019, 25, 1070-1086.	3.2	33
336	A novel messenger RNA and long noncoding RNA signature associated with the progression of nonmuscle invasive bladder cancer. Journal of Cellular Biochemistry, 2019, 120, 8101-8109.	1.2	14
337	Cancer stem cells as a therapeutic target in bladder cancer. Journal of Cellular Physiology, 2019, 234, 3197-3206.	2.0	68
338	Treatment of Metastatic Bladder Cancer. , 2019, , 123-137.		0
339	Management of Urothelial Carcinoma. , 2019, , .		0
340	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. International Journal of Cancer, 2019, 144, 1676-1684.	2.3	57

#	ARTICLE	IF	CITATIONS
341	Suppression of proliferation and activation of cell death by sodium selenite involves mitochondria and lysosomes in chemoresistant bladder cancer cells. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 52, 58-67.	1.5	12
342	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	1.3	9
343	MiR-203a functions as a tumor suppressor in bladder cancer by targeting SIX4. <i>Neoplasma</i> , 2019, 66, 211-221.	0.7	27
344	Standardized terminology systems in cytopathology. <i>Diagnostic Cytopathology</i> , 2019, 47, 53-63.	0.5	18
345	CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of <i>RBI</i> Status. <i>Clinical Cancer Research</i> , 2019, 25, 390-402.	3.2	44
346	Macrophage polarization as a novel weapon in conditioning tumor microenvironment for bladder cancer: can we turn demons into gods?. <i>Clinical and Translational Oncology</i> , 2019, 21, 391-403.	1.2	26
347	Genomic Differences Between Primary and Secondary Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019, 75, 231-239.	0.9	104
348	Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype. <i>Pathology and Oncology Research</i> , 2019, 25, 889-895.	0.9	0
349	Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. <i>European Urology Focus</i> , 2020, 6, 683-697.	1.6	10
350	RNA-Binding Protein <i>ZFP36L1</i> Suppresses Hypoxia and Cell-Cycle Signaling. <i>Cancer Research</i> , 2020, 80, 219-233.	0.4	40
351	An EMT-related gene signature for the prognosis of human bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 605-617.	1.6	132
352	Urinary micro-RNA expressions and protein concentrations may differentiate bladder cancer patients from healthy controls. <i>International Urology and Nephrology</i> , 2020, 52, 461-468.	0.6	20
353	Targeting FGFR in bladder cancer: ready for clinical practice?. <i>Acta Clinica Belgica</i> , 2020, 75, 49-56.	0.5	7
354	Variation in energy metabolism arising from the effect of the tumor microenvironment on cell biological behaviors of bladder cancer cells and endothelial cells. <i>BioFactors</i> , 2020, 46, 64-75.	2.6	8
355	Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. <i>International Journal of Cancer</i> , 2020, 146, 542-552.	2.3	22
356	Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 2636-2647.	2.3	56
357	Depletion of CDC5L inhibits bladder cancer tumorigenesis. <i>Journal of Cancer</i> , 2020, 11, 353-363.	1.2	25
358	Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. <i>Environment International</i> , 2020, 135, 105346.	4.8	25

#	ARTICLE	IF	CITATIONS
359	Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. <i>American Journal of Pathology</i> , 2020, 190, 323-332.	1.9	20
360	Multiparameter urine analysis for quantitative bladder cancer surveillance of orthotopic xenografted mice. <i>Lab on A Chip</i> , 2020, 20, 634-646.	3.1	13
361	Appendix 1: The academic literature used. , 2020, , 109-115.		0
362	GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 1862-1877.	5.0	35
363	Critical treatment choices for patients with platinum-refractory urothelial carcinoma. <i>Lancet Oncology, The</i> , 2020, 21, 11-13.	5.1	1
364	Establishment of resveratrol and its derivatives as neuroprotectant against monocrotophos-induced alteration in NIPBL and POU4F1 protein through molecular docking studies. <i>Environmental Science and Pollution Research</i> , 2020, 27, 291-304.	2.7	4
365	Sex Differences in Urothelial Bladder Cancer Survival. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 26-34.e6.	0.9	42
366	Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 449-458.	0.8	14
367	LncARSR sponges miR-129-5p to promote proliferation and metastasis of bladder cancer cells through increasing SOX4 expression. <i>International Journal of Biological Sciences</i> , 2020, 16, 1-11.	2.6	26
368	EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. <i>Oncogene</i> , 2020, 39, 6856-6870.	2.6	31
369	<p>Identification of FADS1 Through Common Gene Expression Profiles for Predicting Survival in Patients with Bladder Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 8325-8339.	0.9	11
370	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. <i>PLoS ONE</i> , 2020, 15, e0239338.	1.1	14
371	Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. <i>Human Pathology</i> , 2020, 106, 54-61.	1.1	5
372	Non-muscle invasive bladder cancer tissues have increased base excision repair capacity. <i>Scientific Reports</i> , 2020, 10, 16371.	1.6	10
373	Quantitative Proteomics of Urinary Bladder Cancer Cell Lines Identify UAP1 as a Potential Therapeutic Target. <i>Genes</i> , 2020, 11, 763.	1.0	11
374	Small nucleolar RNAs signature (SNORS) identified clinical outcome and prognosis of bladder cancer (BLCA). <i>Cancer Cell International</i> , 2020, 20, 299.	1.8	5
375	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. <i>Cancer Immunology Research</i> , 2020, 8, 1180-1192.	1.6	19
376	Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 162.	1.5	20

#	ARTICLE	IF	CITATIONS
377	The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer. <i>Genes and Diseases</i> , 2021, 8, 781-797.	1.5	11
378	Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer. <i>Cancers</i> , 2020, 12, 3413.	1.7	12
379	SWI/SNF Alterations in Squamous Bladder Cancers. <i>Genes</i> , 2020, 11, 1368.	1.0	3
380	Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. <i>Cancers</i> , 2020, 12, 3541.	1.7	27
381	CTLA-4 +49A/G Polymorphism Increases the Susceptibility to Bladder Cancer in Chinese Han Participants: A Case-Control Study. <i>Disease Markers</i> , 2020, 2020, 1-5.	0.6	7
382	Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 549338.	1.6	5
383	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. <i>Cancers</i> , 2020, 12, 2148.	1.7	27
384	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	157.7	507
385	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020, 126, 4532-4544.	2.0	14
386	Overexpression of reactive oxygen species modulator 1 is associated with advanced grades of bladder cancer. <i>Molecular Biology Reports</i> , 2020, 47, 6497-6505.	1.0	13
387	In Vitro and In Vivo Antitumor Efficacy of Hizikia fusiforme Celluclast Extract against Bladder Cancer. <i>Nutrients</i> , 2020, 12, 2159.	1.7	6
388	Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis. <i>Frontiers in Oncology</i> , 2020, 10, 1142.	1.3	18
389	Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1302.	1.3	26
390	An overview on precision therapy in bladder cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 347-361.	0.4	0
391	lncRNA SNHG1 Promotes Basal Bladder Cancer Invasion via Interaction with PP2A Catalytic Subunit and Induction of Autophagy. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 354-366.	2.3	22
392	Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5670.	1.8	49
393	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , 2020, 6, 65.	2.0	5
394	The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness. <i>Bladder Cancer</i> , 2020, 6, 225-235.	0.2	21

#	ARTICLE	IF	CITATIONS
395	Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. <i>Pathology Research and Practice</i> , 2020, 216, 153186.	1.0	11
396	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
397	Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. <i>Stem Cell Research and Therapy</i> , 2020, 11, 457.	2.4	12
398	Prognostic Stratification of Bladder Cancer Patients with a MicroRNA-Based Approach. <i>Cancers</i> , 2020, 12, 3133.	1.7	8
399	Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1139-1146.	1.3	11
400	Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine. <i>BMC Medical Genomics</i> , 2020, 13, 138.	0.7	4
401	Mutational Landscape and Environmental Effects in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6072.	1.8	30
402	Serum LUCAT1 implicates the pathogenesis of muscle-invasive bladder cancer via targeting miR-199a-5p and miR-199b-5p. <i>Journal of Molecular Histology</i> , 2020, 51, 583-591.	1.0	3
403	Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 ⁺ CD8 ⁺ T cell abundance. <i>Oncolmmunology</i> , 2020, 9, 1810489.	2.1	7
404	Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. <i>Theranostics</i> , 2020, 10, 10078-10091.	4.6	26
405	Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. <i>Oncologist</i> , 2020, 25, e1711-e1719.	1.9	28
406	Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9433.	1.8	9
407	Evaluation of the In Vitro and In Vivo Antitumor Efficacy of Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Against Bladder Cancer. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 8758.	1.3	3
408	The inhibition effect of natural food supplement active ingredients on TP63 carcinoma cell. <i>Medical Oncology</i> , 2020, 37, 120.	1.2	5
409	tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5â€²-tRF-LysCTT Results in Disease Early Progression and Patientsâ€™ Poor Treatment Outcome. <i>Cancers</i> , 2020, 12, 3661.	1.7	31
410	FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 575258.	2.2	46
411	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2020, 21, 61-68.	0.2	2
412	Investigation of Leptin G19A polymorphism with bladder cancer risk: A caseâ€“control study. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23351.	0.9	6

#	ARTICLE	IF	CITATIONS
413	Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder. <i>American Journal of Pathology</i> , 2020, 190, 1752-1762.	1.9	7
414	Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3360.	1.8	12
416	The Changing Landscape of Upper Tract Urothelial Carcinoma Management. <i>Urology</i> , 2020, 145, 316-318.	0.5	0
417	Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure. <i>Molecular and Cellular Biochemistry</i> , 2020, 471, 113-127.	1.4	11
418	Characterization of Brain Metastases in Urothelial Cancers. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e679-e683.	0.9	1
419	MAP kinase-interacting kinase 1 (MNK1) plays as a tumor suppressor in bladder cancer. <i>Translational Cancer Research</i> , 2020, 9, 2588-2598.	0.4	0
420	Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. <i>Cancers</i> , 2020, 12, 1400.	1.7	42
421	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
422	Stromal LAG-3 ⁺ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. , 2020, 8, e000651.		29
423	DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups. <i>Cancer Cell International</i> , 2020, 20, 255.	1.8	14
424	MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI. <i>Frontiers in Pharmacology</i> , 2020, 11, 164.	1.6	16
425	<i>Kdm6a</i> Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with <i>p53</i> Dysfunction. <i>Clinical Cancer Research</i> , 2020, 26, 2065-2079.	3.2	80
426	HDMAC: A Web-Based Interactive Program for High-Dimensional Analysis of Molecular Alterations in Cancer. <i>Scientific Reports</i> , 2020, 10, 3953.	1.6	3
427	Three-Dimensional Microtumors for Probing Heterogeneity of Invasive Bladder Cancer. <i>Analytical Chemistry</i> , 2020, 92, 8768-8775.	3.2	9
428	LncRNA SNHG3 promotes bladder cancer proliferation and metastasis through miR-515a-5p/GINS2 axis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9231-9243.	1.6	49
429	Urobiome in Gender-Related Diversities of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4488.	1.8	16
430	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <i>HRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 5113-5119.	3.2	27
431	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 269-277.	1.4	13

#	ARTICLE	IF	CITATIONS
432	The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer. <i>Oncogene</i> , 2020, 39, 3588-3603.	2.6	24
433	Interactions Between Tumor Biology and Targeted Nanoplatfoms for Imaging Applications. <i>Advanced Functional Materials</i> , 2020, 30, 1910402.	7.8	28
434	Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. <i>Diagnostics</i> , 2020, 10, 39.	1.3	74
435	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	1.9	91
436	Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 456-464.	0.6	6
437	Molecular Insights Into Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 283.	1.8	39
438	Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 207-214.	1.3	5
439	Pedigree analysis of a POLD1 germline mutation in urothelial carcinoma shows a close association between different mutation burdens and overall survival. <i>Cellular and Molecular Immunology</i> , 2021, 18, 767-769.	4.8	2
440	Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. <i>World Journal of Urology</i> , 2021, 39, 425-431.	1.2	10
441	A systematic review on mutation markers for bladder cancer diagnosis in urine. <i>BJU International</i> , 2021, 127, 12-27.	1.3	14
442	The Paris System "atypical urothelial cells" category: can the current criteria be improved?. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 3-8.	0.2	9
444	Advances in bladder cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 104-121.	12.8	320
445	Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions. , 2021, 12, 868.		14
446	Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer. <i>Sensors and Actuators B: Chemical</i> , 2021, 326, 128829.	4.0	10
447	HnRNP-F promotes the proliferation of bladder cancer cells mediated by PI3K/AKT/FOXO1. <i>Journal of Cancer</i> , 2021, 12, 281-291.	1.2	12
448	The role of URO17, a biomarker to enhance diagnosis of urothelial cancer in new hematuria patients' First European Data. <i>BJU Compass</i> , 2021, 2, 46-52.	0.7	14
450	Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. <i>Materials Science and Engineering C</i> , 2021, 119, 111460.	3.8	14
451	Genetic variants in N6-methyladenosine are associated with bladder cancer risk in the Chinese population. <i>Archives of Toxicology</i> , 2021, 95, 299-309.	1.9	18

#	ARTICLE	IF	CITATIONS
452	The Origin of Tumor DNA in Urine of Urogenital Cancer Patients: Local Shedding and Transrenal Excretion. <i>Cancers</i> , 2021, 13, 535.	1.7	9
453	Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110154.	1.4	3
454	Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4036-4050.	0.6	11
455	Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management. <i>Academic Pathology</i> , 2021, 8, 237428952110222.	0.7	2
456	Oxidative stress, epigenetics, and bladder cancer. , 2021, , 67-75.		3
457	Molecular Pathology. , 2021, , 175-188.		0
459	Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. <i>Cancer Management and Research</i> , 2021, Volume 13, 659-675.	0.9	34
460	Testosterone status is not associated with bladder cancer parameters in adult male patients: results of a prospective controlled study. <i>Aging Male</i> , 2021, 24, 101-105.	0.9	4
461	A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 45.	1.2	19
462	Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111077.	2.5	31
463	LncRNA MAFG-AS1 regulates miR-125b-5p/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells. <i>Human Cell</i> , 2021, 34, 588-597.	1.2	24
464	TEAD4 as a Prognostic Marker Promotes Cell Migration and Invasion of Urinary Bladder Cancer via EMT. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 937-949.	1.0	7
465	Gene network screening of bladder cancer via modular analysis. <i>Translational Cancer Research</i> , 2021, 10, 1043-1052.	0.4	0
466	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. <i>Molecular Medicine</i> , 2021, 27, 16.	1.9	32
467	Radiomics Analysis Based on Ultrasound Images to Distinguish the Tumor Stage and Pathological Grade of Bladder Cancer. <i>Journal of Ultrasound in Medicine</i> , 2021, 40, 2685-2697.	0.8	8
468	Identification of deregulation mechanisms specific to cancer subtypes. <i>Journal of Bioinformatics and Computational Biology</i> , 2021, 19, 2140003.	0.3	2
469	Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. <i>Genes</i> , 2021, 12, 260.	1.0	13
470	Correlations between glycolysis with clinical traits and immune function in bladder urothelial carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	5

#	ARTICLE	IF	CITATIONS
471	KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1/c-FOS pathway. <i>Journal of Translational Medicine</i> , 2021, 19, 112.	1.8	15
472	Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis. <i>Oncology Letters</i> , 2021, 21, 344.	0.8	3
473	The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23765.	0.9	8
474	Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 325-335.	1.4	11
475	Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 551605.	1.1	10
476	Biomarker-Oriented Therapy in Bladder and Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2832.	1.8	18
478	Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2553.	1.8	3
479	Circular RNA circGLIS3 promotes bladder cancer proliferation via the miR-1273f/SKP1/Cyclin D1 axis. <i>Cell Biology and Toxicology</i> , 2022, 38, 129-146.	2.4	20
480	FUT7 Promotes the Epithelial-Mesenchymal Transition and Immune Infiltration in Bladder Urothelial Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1069-1084.	1.6	17
481	A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer. <i>PLoS ONE</i> , 2021, 16, e0248342.	1.1	4
482	Routine application of next-generation sequencing testing in uro-oncology: Are we ready for the next step of personalised medicine?. <i>European Journal of Cancer</i> , 2021, 146, 1-10.	1.3	5
483	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like? a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	0.6	6
484	ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21. <i>Cancer Science</i> , 2021, 112, 1758-1771.	1.7	18
485	Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 458.	1.1	14
486	CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 871-887.	2.1	6
487	Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data. <i>International Journal of Urology</i> , 2021, 28, 774-776.	0.5	5
488	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E424-E460.	0.3	7
490	A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder. <i>Bioscience Reports</i> , 2021, 41, .	1.1	12

#	ARTICLE	IF	CITATIONS
491	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021, 220, 153410.	1.0	1
492	APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival. <i>Heliyon</i> , 2021, 7, e06756.	1.4	11
493	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	5.8	159
494	Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. <i>Cancer Letters</i> , 2021, 504, 49-57.	3.2	5
495	Circulating miRNAs Act as Diagnostic Biomarkers for Bladder Cancer in Urine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4278.	1.8	17
496	Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning. <i>Cancers</i> , 2021, 13, 1624.	1.7	17
497	Combination of Urine Exosomal mRNAs and lncRNAs as Novel Diagnostic Biomarkers for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 667212.	1.3	18
498	Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR-145/5p/TOP2A axis. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	10
499	5-ALA-Induced Fluorescent Cytology in the Diagnosis of Bladder Cancer—a Preliminary Report. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 415-420.	0.3	5
500	Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer. <i>Cancers</i> , 2021, 13, 2719.	1.7	8
501	Frontiers in Bladder Cancer Genomic Research. <i>Frontiers in Oncology</i> , 2021, 11, 670729.	1.3	11
502	Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells. <i>Scientific Reports</i> , 2021, 11, 10181.	1.6	12
503	Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 143-148.	0.2	2
504	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327.	1.7	8
505	Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). <i>BMC Cancer</i> , 2021, 21, 593.	1.1	34
506	The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment. <i>Diagnostics</i> , 2021, 11, 863.	1.3	4
507	Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data. <i>International Journal of Urology</i> , 2021, 28, 777-777.	0.5	0
508	Molecular Biology of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 457-468.	0.9	4

#	ARTICLE	IF	CITATIONS
509	Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 701298.	1.3	9
510	Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 574196.	1.1	19
511	Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p. <i>Biochemical Pharmacology</i> , 2021, 188, 114575.	2.0	19
512	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	2
513	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. <i>Translational Andrology and Urology</i> , 2021, 10, 2787-2808.	0.6	7
514	Current Therapy for Metastatic Urothelial Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 469-493.	0.9	4
515	Characterizing the molecular and immune landscape of canine bladder cancer. <i>Veterinary and Comparative Oncology</i> , 2022, 20, 69-81.	0.8	10
516	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. <i>Urology</i> , 2021, 157, 93-101.	0.5	6
517	The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo. <i>Cancer Medicine</i> , 2021, 10, 4437-4450.	1.3	14
518	Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. <i>Frontiers in Nutrition</i> , 2021, 8, 647582.	1.6	57
520	A Comprehensive Bioinformatics Analysis of Notch Pathways in Bladder Cancer. <i>Cancers</i> , 2021, 13, 3089.	1.7	13
521	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 543-555.	1.9	20
522	Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6. <i>Journal of Immunoassay and Immunochemistry</i> , 2021, 42, 662-678.	0.5	7
523	Molecular Classification of Bladder Cancer. , 0, , .		0
524	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 690358.	2.0	6
525	Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β 2 Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 1-10.	1.9	17
526	Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. <i>BMC Cancer</i> , 2021, 21, 858.	1.1	5
527	The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666863.	1.8	11

#	ARTICLE	IF	CITATIONS
528	The Implementation of a Risk Stratification Tool for the Haematuria Clinic to Optimise the Management of Patients with High-Risk Bladder Cancer in the COVID-19 Era. <i>Journal of Endoluminal Endourology</i> , 2021, 4, e20-e27.	0.2	0
529	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. <i>World Journal of Urology</i> , 2021, 39, 4011-4019.	1.2	22
530	Molecular pathology of urothelial carcinoma. <i>Human Pathology</i> , 2021, 113, 67-83.	1.1	24
531	Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. <i>European Urology Focus</i> , 2022, 8, 1256-1269.	1.6	4
532	MD-UNET: Multi-input dilated U-shape neural network for segmentation of bladder cancer. <i>Computational Biology and Chemistry</i> , 2021, 93, 107510.	1.1	16
533	Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 720421.	1.1	9
534	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1481-1492.	0.6	7
535	Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 4673.	1.7	5
536	Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study. <i>BMC Urology</i> , 2021, 21, 136.	0.6	3
537	Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. <i>Cancer Research</i> , 2021, 81, 5161-5175.	0.4	7
538	HSP47 contributes to angiogenesis by induction of CCL2 in bladder cancer. <i>Cellular Signalling</i> , 2021, 85, 110044.	1.7	7
539	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. <i>Cancers</i> , 2021, 13, 4712.	1.7	29
540	SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. <i>Oncogene</i> , 2021, 40, 6081-6092.	2.6	24
541	Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. <i>International Journal of Cancer</i> , 2021, 149, 2099-2115.	2.3	40
542	Improvement of the Collection, Maintenance, and Analysis of Neoplastic Cells from Urine Specimens with the Use of CytoMatrix. <i>Methods and Protocols</i> , 2021, 4, 65.	0.9	0
544	Aberrant FBXW7-mediated ubiquitination and degradation of ZMYND8 enhances tumor progression and stemness in bladder cancer. <i>Experimental Cell Research</i> , 2021, 407, 112807.	1.2	7
545	Primary urothelial carcinoma of the ureter without concurrent renal pelvic or bladder carcinoma: A contemporary clinicopathologic analysis. <i>Pathology Research and Practice</i> , 2021, 226, 153584.	1.0	0
546	Multiplex assays of bladder cancer protein markers with magnetic structural color hydrogel microcarriers based on microfluidics. <i>Sensors and Actuators B: Chemical</i> , 2021, 346, 130464.	4.0	22

#	ARTICLE	IF	CITATIONS
547	WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166271.	1.8	11
548	Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene <i>RGS19</i> (regulator of G protein signaling 19) in bladder cancer. <i>Bioengineered</i> , 2021, 12, 5892-5903.	1.4	6
549	Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells. <i>International Journal of Biological Sciences</i> , 2021, 17, 3456-3475.	2.6	14
550	Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM Remodeling. <i>Cancer Research</i> , 2021, 81, 1552-1566.	0.4	26
551	Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review. <i>Translational Andrology and Urology</i> , 2021, 10, 4022-4035.	0.6	3
552	SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. <i>Cells</i> , 2021, 10, 80.	1.8	12
553	Exosome detection via the ultrafast-isolation system: EXODUS. <i>Nature Methods</i> , 2021, 18, 212-218.	9.0	157
554	Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 807-819.	2.1	12
555	Antitumor potential of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-1H-pyrazoles in human bladder cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 37-46.	2.5	33
556	The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e269-e276.	0.9	39
557	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. <i>Communications Biology</i> , 2020, 3, 784.	2.0	21
558	CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16. <i>Bioscience Reports</i> , 2020, 40, .	1.1	17
559	Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 503-512.	1.1	11
560	Divergent molecular profile of PIK3CA gene in arsenic-associated bladder carcinoma. <i>Mutagenesis</i> , 2020, 35, 499-508.	1.0	4
561	Role of ALDH1a and CD44 in transitional and squamous cell carcinomas of urinary bladder. <i>Egyptian Journal of Pathology</i> , 2017, 37, 137-144.	0.0	1
562	Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. <i>Journal of Urology</i> , 2020, 203, 62-72.	0.2	33
566	A glycolysis-based 4-mRNA signature correlates with the prognosis and cell cycle process in patients with bladder cancer. <i>Cancer Cell International</i> , 2020, 20, 177.	1.8	27
567	New and Emerging Therapies in the Management of Bladder Cancer. <i>F1000Research</i> , 2020, 9, 1146.	0.8	4

#	ARTICLE	IF	CITATIONS
568	BRAF Mutations in Canine Cancers. PLoS ONE, 2015, 10, e0129534.	1.1	95
569	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2016, 11, e0149756.	1.1	66
570	Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. PLoS ONE, 2016, 11, e0165109.	1.1	18
571	Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS ONE, 2017, 12, e0179602.	1.1	24
572	Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine. Balkan Journal of Medical Genetics, 2017, 20, 75-81.	0.5	4
573	A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. Aging, 2020, 12, 2857-2879.	1.4	31
574	High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer. Aging, 2020, 12, 8728-8741.	1.4	15
575	Tumorigenicity of RTK/RAS in urothelium. Oncoscience, 2015, 2, 739-740.	0.9	5
576	Target sequencing and CRISPR/Cas editing reveal simultaneous loss of <i>UTX</i> and <i>UTY</i> in urothelial bladder cancer. Oncotarget, 2016, 7, 63252-63260.	0.8	27
577	Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget, 2016, 7, 67574-67585.	0.8	14
578	Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca ²⁺ signaling in T24M-based bladder cancer models. Oncotarget, 2016, 7, 70750-70768.	0.8	19
579	RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation. Oncotarget, 2016, 7, 69159-69172.	0.8	23
580	Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget, 2016, 7, 76374-76389.	0.8	32
581	E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3K ^{Î²} silencing. Oncotarget, 2016, 7, 84054-84071.	0.8	10
582	The role of tumor microenvironment in therapeutic resistance. Oncotarget, 2017, 8, 3933-3945.	0.8	189
583	Opposing roles of <i>PIK3CA</i> gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget, 2017, 8, 10531-10542.	0.8	11
584	Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer. Oncotarget, 2017, 8, 24483-24490.	0.8	20
585	MicroRNAs in biofluids are novel tools for bladder cancer screening. Oncotarget, 2017, 8, 32370-32379.	0.8	43

#	ARTICLE	IF	CITATIONS
586	Identification of long non-coding RNAs that stimulate cell survival in bladder cancer. <i>Oncotarget</i> , 2017, 8, 34442-34452.	0.8	12
587	Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. <i>Oncotarget</i> , 2017, 8, 44326-44334.	0.8	19
588	Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis. <i>Oncotarget</i> , 2017, 8, 102898-102911.	0.8	10
589	Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities. <i>Oncotarget</i> , 2018, 9, 3172-3187.	0.8	5
590	Identification of bladder cancer prognostic biomarkers using an ageing gene-related competitive endogenous RNA network. <i>Oncotarget</i> , 2017, 8, 111742-111753.	0.8	7
591	“Two hits - one stone”, increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signaling. <i>Oncotarget</i> , 2018, 9, 32448-32465.	0.8	35
592	XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. <i>Oncotarget</i> , 2018, 9, 34567-34581.	0.8	18
593	IGFBP-2 acts as a tumour suppressor and plays a role in determining chemosensitivity in bladder cancer cells. <i>Oncotarget</i> , 2019, 10, 7043-7057.	0.8	8
594	Targeting Hsp90 in urothelial carcinoma. <i>Oncotarget</i> , 2015, 6, 8454-8473.	0.8	31
595	Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer. <i>Oncotarget</i> , 2015, 6, 39821-39838.	0.8	22
596	A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. <i>Oncotarget</i> , 2015, 6, 42258-42275.	0.8	40
597	The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence. <i>Oncotarget</i> , 2015, 6, 35231-35246.	0.8	26
598	Novel variants in <i>MLL</i> confer to bladder cancer recurrence identified by whole-exome sequencing. <i>Oncotarget</i> , 2016, 7, 2629-2645.	0.8	25
599	Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage. <i>Oncotarget</i> , 2016, 7, 22556-22565.	0.8	25
600	Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis. <i>Oncotarget</i> , 2016, 7, 23947-23960.	0.8	21
601	JNK2 downregulation promotes tumorigenesis and chemoresistance by decreasing p53 stability in bladder cancer. <i>Oncotarget</i> , 2016, 7, 35119-35131.	0.8	12
602	Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
603	Liquid biopsies for surveillance and monitoring treatment response of bladder cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 379-379.	0.7	2

#	ARTICLE	IF	CITATIONS
604	Ezh2-dependent therapies in bladder cancer: synthetic lethality. <i>Annals of Translational Medicine</i> , 2017, 5, 494-494.	0.7	3
605	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 1-12.	3.9	13
606	Identification of Deregulated Transcription Factors Involved in Specific Bladder Cancer Subtypes. , 0, , .		1
607	Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3735-3746.	0.5	4
608	Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 587.	0.9	9
609	Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review). <i>Molecular Medicine Reports</i> , 2020, 22, 5003-5011.	1.1	8
610	LINC01638 lncRNA mediates the postoperative distant recurrence of bladder cancer by upregulating ROCK2. <i>Oncology Letters</i> , 2019, 18, 5392-5398.	0.8	9
611	Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 92-8.	0.7	23
612	Urinary bladder cancer: biomarkers and target therapy, new era for more attention. <i>Oncology Reviews</i> , 2016, 10, 320.	0.8	23
613	S100A12 and RAGE Expression in Human Bladder Transitional Cell Carcinoma: a Role for the Ligand/RAGE Axis in Tumor Progression?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2725-2729.	0.5	32
614	Cancer molecular biology and strategies for the design of cytotoxic gold(Au^{I}) and gold(Au^{III}) complexes: a tutorial review. <i>Dalton Transactions</i> , 2021, 50, 17413-17437.	1.6	17
615	Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes. <i>Journal of Immunology Research</i> , 2021, 2021, 1-26.	0.9	14
616	Current status of organoid culture in urological malignancy. <i>International Journal of Urology</i> , 2021, , .	0.5	3
617	KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 4837.	1.0	11
618	Urothelial cancer organoids: a tool for bladder cancer research. <i>Der Pathologe</i> , 2021, 42, 165-169.	0.7	2
619	FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients. <i>BMC Urology</i> , 2021, 21, 143.	0.6	5
620	Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. <i>Journal of Pathology</i> , 2022, 256, 108-118.	2.1	12
621	The Role of Kinase Inhibitors in Cancer Therapies. <i>Biochemistry</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
622	Pharmacophore Based Design Of Probable Fgfr-1 Inhibitors From The 3d Crystal Structure Of Infigratinib - A Drug Used In The Treatment Of Cholangiocarcinomas. Letters in Drug Design and Discovery, 2021, 18, .	0.4	0
623	Associations between inflammasome-related gene NLRP3 Polymorphisms (rs10754558 and rs35829419) and risk of bladder cancer in a Chinese population. Journal of Clinical Laboratory Analysis, 2021, 35, e23973.	0.9	8
624	XRCC1 codon 399 polymorphism (RS25487) in the Ukrainian population. Faktori Eksperimental Noi Evolucii Organizmiv, 0, 21, 325-329.	0.0	0
625	Urinary Bladder. , 2016, , 1681-1735.		0
626	Urothelial Carcinoma. , 2016, , 8-148-8-153.		0
627	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2016, , 1-43.		0
628	Pathogenesis of Urothelial Carcinoma. , 2016, , 1-4.		0
630	The Molecular Mechanisms of Tobacco in Cancer Pathogenesis. Iranian Journal of Cancer Prevention, 2017, In Press, .	0.7	1
631	Molecular Carcinogenesis of Urinary Bladder Cancer. , 2017, , 191-205.		0
632	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2017, , 839-881.		0
633	The Value of Anti-angiogenics in Bladder Cancer Therapy. , 2017, , 1-13.		1
634	Prognostic value of HER-2/neu, Ki-67, MCM-2, and p21 expression in nonmuscle invasive bladder cancer. Egyptian Journal of Pathology, 2017, 37, 352-359.	0.0	0
636	Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 49.	0.0	2
637	Developments in the area of bladder cancer genomics and its importance in the treatment selection. , 2018, 02, .		2
638	Genetics Factors and Tumor Markers in Upper Urinary Tract-Urothelial Carcinoma. , 2018, , 71-83.		0
641	Epidemiology, Etiology, and Histopathology. , 2019, , 3-7.		0
642	The Value of Anti-angiogenics in Bladder Cancer Therapy. , 2019, , 593-605.		0
643	Micropapillary Carcinoma of the Bladder: Recent Advances. Annals of Urologic Oncology, 2019, , 1-10.	0.0	0

#	ARTICLE	IF	CITATIONS
644	Interplay of host genome and tumour genome in bladder cancer. Faktori Eksperimental Noi Evolucii Organizmiv, 0, 24, 233-238.	0.0	0
647	MOLECULAR SUBTYPES OF MUSCULAR INVASIVE BLADDER CANCER. Proceedings of the Shevchenko Scientific Society Medical Sciences, 2020, 59, .	0.3	0
648	Molecular subtypes of a bladder cancer: evolution of classifications and clinical significance. Klinichna Khirurgiia, 2020, 87, 92-99.	0.0	0
649	GENOMICS OF BLADDER CANCER. Fiziolohichni Zhurnal (Kiev, Ukraine: 1994), 2020, 66, 83-92.	0.1	0
650	Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing. Cancer Biology and Therapy, 2020, 21, 709-716.	1.5	6
651	Development of a novel prognostic signature for predicting the overall survival of bladder cancer patients. Bioscience Reports, 2020, 40, .	1.1	3
652	Aberrantly glycosylated integrin $\alpha 3 \beta 1$ is a unique urinary biomarker for the diagnosis of bladder cancer. Aging, 2020, 12, 10844-10862.	1.4	5
653	Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis. , 2021, , 141-157.		1
654	PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer. Frontiers in Immunology, 2021, 12, 705086.	2.2	12
655	Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?. Metabolites, 2021, 11, 756.	1.3	10
656	YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1. Bioengineered, 2021, 12, 9150-9161.	1.4	12
657	Long non-coding RNA EGFR-AS1 sponges micorRNA-381 to upregulate ROCK2 in bladder cancer. Oncology Letters, 2020, 19, 1899-1905.	0.8	5
658	Molecular pathology of urothelial carcinoma: prognostic and predictive biomarkers. Practical Oncology, 2020, 2, 2-10.	0.1	2
659	The analysis of a ceRNA network and the correlation between lncRNA, miRNA, and mRNA in bladder cancer. Translational Cancer Research, 2020, 9, 869-881.	0.4	2
660	Developing Biomarkers and New Therapeutic Targets in Muscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2020, 18, 1-10.	0.1	1
661	Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models. Cancer Diagnosis & Prognosis, 2021, 1, 245-263.	0.3	2
662	Proteomics as a Complementary Technique to Characterize Bladder Cancer. Cancers, 2021, 13, 5537.	1.7	4
663	New Salvage Treatments for Metastatic Bladder Cancer. Bladder Cancer, 2020, 6, 399-400.	0.2	0

#	ARTICLE	IF	CITATIONS
664	Bladder Pathology. , 2021, , 87-115.		0
665	Prostate stem cell antigen variation rs2294008 associated with the risk of bladder cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 13259-66.	1.3	2
666	ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPES. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2016, 21, 405-16.	0.7	38
667	Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies as a prognostic biomarker for basal-like bladder cancer. American Journal of Cancer Research, 2017, 7, 1850-1862.	1.4	5
668	A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival. Iranian Journal of Pharmaceutical Research, 2020, 19, 355-365.	0.3	2
669	Identification and validation of an immune-related gene-based prognostic index for bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 5188-5204.	0.0	6
670	Role of immunotherapy in localized muscle invasive urothelial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045858.	1.4	4
671	(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder. Cancers, 2021, 13, 5642.	1.7	4
672	Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 25-36.	0.8	14
673	Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma. Cancers, 2021, 13, 6040.	1.7	15
674	Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies. Future Oncology, 2022, 18, 105-115.	1.1	6
676	A New Ferroptosis-Related lncRNA Signature Predicts the Prognosis of Bladder Cancer Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 699804.	1.8	31
677	Prognostic significance of LRIG2 and LRIG3 proteins in urothelial bladder carcinoma. Journal of Immunoassay and Immunochemistry, 2021, , 1-25.	0.5	0
678	Proteomic Profiling of Plasma-Derived Biomarkers in Patients with Bladder Cancer: A Step towards Clinical Translation. Life, 2021, 11, 1294.	1.1	8
679	Renin-Angiotensin System Single Nucleotide Polymorphisms Are Associated with Bladder Cancer Risk. Current Oncology, 2021, 28, 4702-4708.	0.9	2
680	Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 764125.	1.8	4
681	The Prognostic Significance of Proteasome 26S Subunit, Non-ATPase (PSMD) Genes for Bladder Urothelial Carcinoma Patients. Cancer Informatics, 2021, 20, 117693512110676.	0.9	13
682	Exploiting protein family and protein network data to identify novel drug targets for bladder cancer. Oncotarget, 2022, 13, 105-117.	0.8	2

#	ARTICLE	IF	CITATIONS
683	Biomaterials assisted reconstructive urology: The pursuit of an implantable bioengineered neo-urinary bladder. <i>Biomaterials</i> , 2022, 281, 121331.	5.7	11
684	Role of p53 in Human Cancers. , 0, , .		1
685	Exposureâ€“response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 151-164.	1.1	5
688	Tumor-specific imaging probes in preclinical applications and clinical trials. , 2022, , 49-138.		0
689	EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation. <i>Cell Death and Disease</i> , 2022, 13, 39.	2.7	10
690	Immunometabolism in the Bladder Cancer Microenvironment. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1201-1216.	0.6	4
691	Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 197.e11-197.e23.	0.8	2
692	Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments. <i>Molecular Therapy</i> , 2022, 30, 1054-1070.	3.7	62
693	Advances in Management of Bladder Cancerâ€“The Role of Photodynamic Therapy. <i>Molecules</i> , 2022, 27, 731.	1.7	31
694	Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy. <i>Molecular Biology Reports</i> , 2022, 49, 2755-2763.	1.0	1
695	Downregulation of m ⁶ A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. <i>Molecular Oncology</i> , 2022, 16, 1841-1856.	2.1	10
696	Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114118.	2.6	31
697	Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. <i>Clinical Epigenetics</i> , 2022, 14, 19.	1.8	16
698	EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors. <i>Molecular Imaging and Biology</i> , 2022, 24, 511-518.	1.3	5
700	Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation. <i>Cancer Cell International</i> , 2021, 21, 655.	1.8	8
702	Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, , .	0.9	0
703	Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 810272.	1.8	5
704	Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. <i>Cancers</i> , 2022, 14, 969.	1.7	2

#	ARTICLE	IF	CITATIONS
705	Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure. <i>Frontiers in Oncology</i> , 2022, 12, 796407.	1.3	3
707	Immunosuppressive tumor-associated macrophages expressing interleukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
708	Overexpression of miRNA-93-5p Promotes Proliferation and Migration of Bladder Urothelial Carcinoma via Inhibition of KLF9. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-12.	0.7	4
709	Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing. <i>Frontiers in Genetics</i> , 2022, 13, 831146.	1.1	5
710	Conflicting Roles of ZFP36L1 in Regulating the Progression of Muscle Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 687786.	1.6	0
711	BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance. <i>Biochemistry and Cell Biology</i> , 2022, 100, 179-187.	0.9	5
712	The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma. <i>BMC Urology</i> , 2022, 22, 51.	0.6	7
713	In vitro and in vivo anti-tumor efficacy of krill oil against bladder cancer: Involvement of tumor-associated angiogenic vasculature. <i>Food Research International</i> , 2022, 156, 111144.	2.9	7
714	Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 173, 106167.	1.9	3
715	A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/ β -catenin signaling pathway. <i>PeerJ</i> , 2022, 10, e13220.	0.9	4
716	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4173.	1.8	40
723	Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 449-455.	1.1	9
724	AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients' biopsies and matched urine.. <i>Pan African Medical Journal</i> , 2022, 41, 59.	0.3	2
726	New Prognostic Gene Signature and Immune Escape Mechanisms of Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	3
727	Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma. <i>Frontiers in Urology</i> , 2022, 2, .	0.2	1
728	Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. <i>BMC Cancer</i> , 2022, 22, 478.	1.1	8
729	Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 83-92.	1.4	3
730	The Immunohistochemical Expression of SOX-10 in Urothelial Carcinoma and the Non Neoplastic Urothelium; and a Correlation with the Tumor Features. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1425-1432.	0.5	1

#	ARTICLE	IF	CITATIONS
731	CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200/CDC25B pathway. <i>Cell Biology and Toxicology</i> , 2023, 39, 1-18.	2.4	7
732	Laminin-integrin $\alpha 6 \beta 4$ interaction activates notch signaling to facilitate bladder cancer development. <i>BMC Cancer</i> , 2022, 22, 558.	1.1	3
734	Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. <i>Future Oncology</i> , 2022, 18, 2599-2614.	1.1	10
735	Modified Titanium Dioxide as a Potential Visible-Light-Activated Photosensitizer for Bladder Cancer Treatment. <i>ACS Omega</i> , 2022, 7, 17563-17574.	1.6	2
736	A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA. <i>BioMed Research International</i> , 2022, 2022, 1-19.	0.9	1
737	Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature. <i>Cancers</i> , 2022, 14, 2542.	1.7	3
738	The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer. <i>Metabolites</i> , 2022, 12, 488.	1.3	5
740	Tumors of the Urinary Bladder. , 2021, , 345-559.		0
741	Reply to Yuxuan Song, Caipeng Qin, and Tao Xu's Letter to the Editor re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. <i>Eur Urol</i> 2022;81:331-6. <i>European Urology</i> , 2022, 82, e78-e79.	0.9	0
742	Precursors of urinary bladder cancer: molecular alterations and biomarkers. <i>Human Pathology</i> , 2023, 133, 5-21.	1.1	2
743	The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
745	Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. , 0, , 45-60.		1
746	Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 2033-2039.	1.2	11
747	Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10
748	Persistent γ -H2AX Formation and Expression of Stem Cell Markers in N-Butyl-N-(4-Hydroxybutyl)Nitrosamine-Induced Bladder Carcinogenesis in Rats. <i>Toxicological Sciences</i> , 0, , .	1.4	4
749	The dynamic roles of the bladder tumour microenvironment. <i>Nature Reviews Urology</i> , 2022, 19, 515-533.	1.9	24
750	Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7057.	1.8	1
751	Clinical potential of the Hippo-YAP pathway in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
752	Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B. <i>World Journal of Urology</i> , 2022, 40, 2267-2273.	1.2	5
753	Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7819.	1.8	7
754	Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
755	Bladder cancer, inflammaging and microbiomes. <i>Nature Reviews Urology</i> , 2022, 19, 495-509.	1.9	29
756	PODNL1 promotes cell migration and regulates the epithelial/mesenchymal transition process in bladder cancer. <i>Biochemical and Biophysical Research Communications</i> , 2022, 620, 165-172.	1.0	4
757	Bacteria for Treatment: Microbiome in Bladder Cancer. <i>Biomedicines</i> , 2022, 10, 1783.	1.4	4
759	Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications. <i>International Journal of Biological Macromolecules</i> , 2022, 218, 394-408.	3.6	13
760	Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications. <i>Anticancer Research</i> , 2022, 42, 3767-3778.	0.5	4
761	Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin. <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	2
762	Targeting bladder urothelial carcinoma with pHILIP-ICG and inhibition of urothelial cancer cell proliferation by pHILIP-amanitin. <i>Frontiers in Urology</i> , 0, 2, .	0.2	2
763	<i>N</i> -((3,4-dimethoxyphenethyl)amino)methyl-2,3,4,9-tetrahydro-1 <i>H</i> -carbazol-1-amine inhibits bladder cancer progression by suppressing <i>YAP1</i> / <i>TAZ</i> . <i>Genes To Cells</i> , 0, , .	0.5	2
764	Early detection of urinary bladder carcinogens in rats by immunohistochemistry for γ -H2AX: a review from analyses of 100 chemicals. <i>Journal of Toxicologic Pathology</i> , 2022, 35, 283-298.	0.3	6
765	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2022, , 975-1022.		0
766	<i>Rosa hybrida</i> Petal Extract Exhibits Antitumor Effects by Abrogating Tumor Progression and Angiogenesis in Bladder Cancer Both In Vivo and In Vitro. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211143.	0.8	3
767	Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211262.	0.6	6
768	The Oncobiome in Gastroenteric and Genitourinary Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9664.	1.8	6
769	Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 538.e15-538.e24.	0.8	1
770	Interaction between <i>HER2</i> and <i>ATM</i> predicts poor survival in bladder cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	1.6	2

#	ARTICLE	IF	CITATIONS
771	Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1047-1055.	1.0	3
772	Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2022, 14, 4570.	1.7	0
773	Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing. <i>Laboratory Medicine</i> , 2023, 54, 142-152.	0.8	1
774	GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2022, 130, 10-17.	1.1	7
775	Role of the JNK Pathway in Bladder Cancer. <i>OncoTargets and Therapy</i> , 0, Volume 15, 963-971.	1.0	4
776	HOXA1 promotes proliferation and metastasis of bladder cancer by enhancing SMAD3 transcription. <i>Pathology Research and Practice</i> , 2022, 239, 154141.	1.0	7
777	ELK1 suppresses SYTL1 expression by recruiting HDAC2 in bladder cancer progression. <i>Human Cell</i> , 2022, 35, 1961-1975.	1.2	2
778	Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
779	Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with <i>FGF/FGFR</i> Aberrations Across Urinary Tract Tumors. <i>Oncologist</i> , 2023, 28, e82-e91.	1.9	2
780	A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. <i>Medicine (United States)</i> , 2022, 101, e30893.	0.4	3
781	Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
782	N6-methyladenosine-related single-nucleotide polymorphism analyses identify oncogene RNFT2 in bladder cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	2
783	Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 311-322.	2.3	4
784	Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer. <i>Cancer Letters</i> , 2022, 550, 215924.	3.2	2
785	Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma—A Cost-Effectiveness Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, .	0.9	1
786	FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i> mRNA Expression. <i>Journal of Clinical Oncology</i> , 2023, 41, 629-639.	0.8	21
787	Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1
788	Single-cell sequencing technologies in bladder cancer research: Applications and challenges. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4

#	ARTICLE	IF	CITATIONS
790	A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
791	Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-“programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study. <i>European Urology Open Science</i> , 2023, 47, 48-57.	0.2	2
792	The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization. <i>Seminars in Radiation Oncology</i> , 2023, 33, 1-11.	1.0	0
793	STIL Promotes Tumorigenesis of Bladder Cancer by Activating PI3K/AKT/mTOR Signaling Pathway and Targeting C-Myc. <i>Cancers</i> , 2022, 14, 5777.	1.7	3
794	Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. <i>Drugs</i> , 2022, 82, 1649-1662.	4.9	5
795	MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway. <i>Pharmacogenetics and Genomics</i> , 2023, 33, 1-9.	0.7	2
796	Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	0
797	A novel deep learning segmentation model for organoid-based drug screening. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
798	Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate. <i>Biomaterials Research</i> , 2022, 26, .	3.2	5
799	Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives. <i>Urologia</i> , 2023, 90, 3-10.	0.3	2
800	Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. <i>Cancer Cell</i> , 2022, 40, 1550-1565.e7.	7.7	39
802	A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
803	Immunohistochemical Algorithm for the Classification of Muscle-Invasive Urinary Bladder Carcinoma with Lymph Node Metastasis: An Institutional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7430.	1.0	0
804	The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 964.	1.8	2
805	Alternative splicing event associated with immunological features in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
807	Polymorphic renal transporters and cisplatin-™s toxicity in urinary bladder cancer patients: current perspectives and future directions. , 2023, 40, .		3
808	The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy. <i>Medicine (United States)</i> , 2022, 101, e31973.	0.4	0
809	An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. <i>Veterinary Sciences</i> , 2023, 10, 19.	0.6	4

#	ARTICLE	IF	CITATIONS
810	Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment. <i>Biomedicines</i> , 2023, 11, 69.	1.4	1
811	The biological impacts of CEBPD on urothelial carcinoma development and progression. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
812	Oxidative Stress Markers in Urine and Serum of Patients with Bladder Cancer. <i>Antioxidants</i> , 2023, 12, 277.	2.2	1
813	Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer. <i>Translational Andrology and Urology</i> , 2023, .	0.6	0
814	Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis. <i>Journal of Pathology</i> , 2023, 259, 455-467.	2.1	6
815	Urinary Eubacterium sp. CAG:581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway. <i>Cancers</i> , 2023, 15, 809.	1.7	3
816	Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
817	Evaluation of the Small Heat Shock Protein Family Members HSPB2 and HSPB3 in Bladder Cancer Prognosis and Progression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2609.	1.8	0
818	Androgen receptor-dependent regulation of metabolism in high grade bladder cancer cells. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
819	A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients. <i>Human Cell</i> , 0, , .	1.2	0
820	Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	3
821	Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	6
822	Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer. <i>Cellular and Molecular Biology Letters</i> , 2023, 28, .	2.7	6
823	Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets. <i>Modern Pathology</i> , 2023, 36, 100120.	2.9	1
824	Electrochemical immunosensor utilizing a multifunctional 3D nanocomposite coating with antifouling capability for urinary bladder cancer diagnosis. <i>Sensors and Actuators B: Chemical</i> , 2023, 384, 133621.	4.0	8
825	Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder. <i>Experimental and Molecular Pathology</i> , 2023, 131, 104860.	0.9	2
826	The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells. <i>Tissue and Cell</i> , 2023, 82, 102096.	1.0	0
827	Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature. <i>Translational Oncology</i> , 2023, 29, 101629.	1.7	2

#	ARTICLE	IF	CITATIONS
828	Tumor organoid biobank-new platform for medical research. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
829	Overexpression of KMT9 ^{1±} Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer. <i>Cells</i> , 2023, 12, 589.	1.8	3
830	The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer. <i>Biomedicines</i> , 2023, 11, 539.	1.4	2
831	Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of Nanopporterâ€œEncased Hydrogel Eradicates Bladder Carcinoma. <i>Advanced Science</i> , 2023, 10, .	5.6	4
833	Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	1
836	Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 287-304.	12.5	34
837	The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-Iâ€œMediated Immune Response. <i>Cancer Research</i> , 2023, 83, 1834-1850.	0.4	5
838	Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 840-847.	1.1	2
839	CircRPPH1 accelerates the proliferation and migration of bladder cancer via enhancing the STAT3 signaling pathway. <i>Oncology Reports</i> , 2023, 49, .	1.2	3
840	MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 0, , .	2.2	1
841	Recent advances in the understanding of urothelial tumorigenesis. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-9.	1.1	0
842	LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
843	Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. <i>PLoS Genetics</i> , 2023, 19, e1010575.	1.5	6
844	High-Intensity Training for Knee Osteoarthritis: A Narrative Review. <i>Sports</i> , 2023, 11, 91.	0.7	0
845	Detection of the <sc><i>ADGRG6</i></sc> hotspot mutations in urine for bladder cancer early screening by <sc>ARMSâ€œqPCR</sc>. <i>Cancer Medicine</i> , 2023, 12, 11503-11512.	1.3	1
848	Translational Science. , 2023, , 514-532.		0
849	BCG Immunotherapy: Old Tool and New Concepts. , 2022, , 1-23.		0
859	Cancers du rein et des voies urinaires. , 2023, , 207-209.		0

#	ARTICLE	IF	CITATIONS
868	Assessment of PD-L1 Status in Urothelial Cancer. <i>Methods in Molecular Biology</i> , 2023, , 249-255.	0.4	0
869	Evaluation of FGFR Alteration Status in Urothelial Tumors. <i>Methods in Molecular Biology</i> , 2023, , 283-291.	0.4	0
870	A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures. <i>Methods in Molecular Biology</i> , 2023, , 59-99.	0.4	0
898	Molecular Pathology of Urinary Bladder Tumors. , 2023, , 401-422.		0
912	Nanomedicines in Treatment of Cancer. <i>Learning Materials in Biosciences</i> , 2023, , 183-211.	0.2	0
925	Harnblasenkrebs. , 2024, , 355-373.		0